HCW Biologics (HCW Biologics) FCF Margin % : -574.85% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is HCW Biologics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. HCW Biologics's Free Cash Flow for the three months ended in Dec. 2023 was $-7.61 Mil. HCW Biologics's Revenue for the three months ended in Dec. 2023 was $1.32 Mil. Therefore, HCW Biologics's FCF Margin % for the quarter that ended in Dec. 2023 was -574.85%.

As of today, HCW Biologics's current FCF Yield % is -69.02%.

The historical rank and industry rank for HCW Biologics's FCF Margin % or its related term are showing as below:

HCWB' s FCF Margin % Range Over the Past 10 Years
Min: -1010.45 Med: -307.36 Max: -258.98
Current: -1010.45

During the past 5 years, the highest FCF Margin % of HCW Biologics was -258.98%. The lowest was -1010.45%. And the median was -307.36%.

HCWB's FCF Margin % is ranked worse than
75.57% of 1048 companies
in the Biotechnology industry
Industry Median: -144.01 vs HCWB: -1010.45

HCW Biologics FCF Margin % Historical Data

The historical data trend for HCW Biologics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HCW Biologics FCF Margin % Chart

HCW Biologics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-258.98

-307.36

-1,010.45

HCW Biologics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial												-287.48	-9,376.19	-1,757.46	-729.07	-574.85

Competitive Comparison of HCW Biologics's FCF Margin %

For the Biotechnology subindustry, HCW Biologics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HCW Biologics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where HCW Biologics's FCF Margin % falls into.

HCW Biologics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

HCW Biologics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-28.717	/	2.842
	=	-1,010.45 %

HCW Biologics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-7.611	/	1.324
	=	-574.85 %

HCW Biologics FCF Margin % Related Terms

Thank you for viewing the detailed overview of HCW Biologics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

HCW Biologics (HCW Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HCW Biologics Inc (NAS:HCWB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2929 N Commerce Parkway, Miramar, FL, USA, 33025

Website

https://www.hcwbiologics.com

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company believes age-related low-grade chronic inflammation is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases.

Executives

Gary M Winer	director	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Hing C Wong	director, officer: Chief Executive Officer	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rebecca Byam	officer: Chief Financial Officer	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lee Flowers	officer: SVP of Business Development	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rick S. Greene	director	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Jin-an Jiao	officer: VP of Development	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lisa M. Giles	director	DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Scott T Garrett	director	35 CROSBY DRIVE, BEDFORD MA 01730
Peter Rhode	officer: See Remarks	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Medmira Capital Ltd.	10 percent owner	16F BEIKE BUILDING, 59 GAOXIN NANJIU RD, SHENZHEN F4 518057